European regulators approve Takeda’s acquisition of Shire after divestment

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/AndreyPopov)
(Image: Getty/AndreyPopov)

Related tags: Ema, Divest, regulatory approval, European commission

Takeda’s aim to acquire Shire for $62bn received a boost after regulators vote positively to approve the transaction following the divestment of Shire’s IBD drug.

The European Commission​ gave approval to the $62bn (€54.4) takeover​ subject to the divestment of a Shire drug in development.

The company previously proposed the divestment​ of Shire’s drug candidate SHP647, for the treatment of inflammatory bowel disease (IBD). Takeda’s highest-selling drug, Entyvio (vedolizumab), is also for the treatment of IBD. 

Regulators in the US, Japan, China, and Brazil have already approved this acquisition.

Takeda agreed to buy Shire with a bid of 46% cash and 54% stock meaning Shire shareholders would own half of the merged company. Shire initially rejected​ Takeda’s proposal.

An investor vote​ is set for next month, needing two-thirds of its shareholders to support the deal in order for it to be approved. The company previously stated that debt burden is a concern for Takeda and its shareholders, as the company would be reliant on a $30.9bn bridge loan to finance the acquisition.

London-listed Shire’s shares rose 3% recently. The shares hit the highest share level since Takeda first announced its interest in acquiring the company.

Related news

Show more

Related product

Related suppliers

Follow us

Products

View more

Webinars